Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions

1

Do I needsurgery?

Do I needchemotherapy?

Do I needradiation?

INVASIVEBREAST CANCER

DCISBREAST CANCER PROSTATE CANCER

Do I have aggressivedisease?

STAGE II/IIICOLON CANCER

Genomic Health Has Provided It’s Oncotype DX Breast, Colon, and Prostate Cancer Tests to Help More Than

350,000 Patients

Oncotype DX Changed Treatment Decisions in Over One-Third of Breast Cancer Patients Leading to Less Toxicity and Healthcare Costs

2* Based on meta-analysis of seven studies with 912 patients

Chemotherapy No Chemotherapy

Women Diagnosed with Breast CancerTreatment Plan Prior to Oncotype DXTreatment Plan After Oncotype DX • Chemotherapy recommended for 62% of patients• Over a 37% Change in Treatment Decisions

Do I needchemotherapy?

INVASIVEBREAST CANCER

Accurate Prediction of Prostate Cancer Risk is Needed at Time of Biopsy

3

Do I needsurgery?

PROSTATE CANCER

Oncotype DX Genomic Prostate Score Provides Significant Clinical Advantages and Actionable Information

• Optimized technology to analyze tiny needle biopsies

• Identified genes that predict disease aggressiveness and address tumor heterogeneity

• Established multiple biological pathways are highly significant

• Studied relevant patient populations

• Developed to answer critical treatment questions prior to intervention

4

"These results have the potential to change medical practice significantly by providing physicians and their patients with a multi-gene prostate cancer test, designed specifically for biopsies, that will improve treatment decisions for early-stage prostate cancer at the time of diagnosis.”

—Peter Carroll, M.D., M.P.H.Chair, Department of Urology, University of California, San Francisco and Lead Investigator

Prostate Clinical Validation Study(American Urological Association

Meeting May 2013)